Novartis announced that patients with Myelofibrosis initially randomized to treatment with Jakavi (ruxolitinib) lived longer than those randomized to treatment...
Results from a Phase III three-year follow-up study that showed Jakafi/Jakavi (ruxolitinib), from Novartis, demonstrated improved overall survival and sustained...
Background and objectives: Advocates for dementia-friendly communities emphasize the need for the public to know about the dementias and to experience social comfort with people having dementia.
We propose an integrated and adaptable approach to improve patient care and clinical outcomes through analgesia and light sedation, initiated early during an episode of critical illness and as a priority of care.
Can-Fite BioPharma announced that Dr. Kim A. Papp, MD, PhD, presented new data from the Company’s recently completed Phase III COMFORT study at the late-breaking news session of the 31st European Academy of Dermatology and Venerology (EADV) Congress
The FDA on 16 November 2011, approved Jakafi(ruxolitinib),from Incyte/Novartis, the first drug approved to specifically treat patients with the bone...
Imodium Plus Comfort tablets are indicated for the symptomatic treatment of acute diarrhoea in adults and adolescents over 12 years when acute diarrhoea is associated with gas-related abdominal discomfort including bloating, cramping or flatulence.
Royal Philips announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation